Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act of 2025
HB1796, titled the Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act of 2025, would reauthorize and expand a federal demonstration program under the Public Health Service Act focused on sickle cell disease. The bill updates the program’s purpose language to emphasize not only treatment and prevention of sickle cell disease itself, but also the prevention and treatment of complications associated with the disease. It also broadens the types of federal partnerships allowed by authorizing grants, contracts, or cooperative agreements.
The bill increases the authorized funding level for the program from $4,455,000 per year for fiscal years 2019 through 2023 to $8,205,000 per year for fiscal years 2025 through 2029. In addition, it includes a sense of Congress statement encouraging further research into the causes of heritable blood disorders and the development of cures, signaling a broader federal interest in research, surveillance, prevention, and treatment beyond the existing demonstration program.
The bill would amend Section 1106(b) of the Public Health Service Act, changing the statutory focus from general sickle cell disease prevention and treatment to a more specific emphasis on treatment and on preventing and treating complications of the disease. It would also expand the federal government’s contracting authority and raise the program’s authorization level, which could affect HHS-administered grants, research partnerships, and treatment initiatives for sickle cell disease and related heritable blood disorders. The primary affected parties would be federal health agencies, researchers, health providers, and patients with sickle cell disease or other inherited blood disorders.
The available context suggests generally positive sentiment toward the bill, with bipartisan sponsorship from several House members and no recorded votes or committee objections in the provided materials. The bill’s framing as a reauthorization and funding increase for a serious health condition indicates support for continued federal involvement in research and treatment. The absence of committee transcript debate or vote data limits the ability to identify broader political division, but the bill appears to be a relatively noncontroversial health measure at introduction.
No specific contention is documented in the provided committee materials or voting history. Potential points of policy interest, however, include the increased authorization level, the expansion from prevention of sickle cell disease to prevention and treatment of complications, and the broader research mandate for heritable blood disorders. If any disagreement were to arise, it would likely concern federal spending levels, the scope of the program, or how broadly the research and treatment authority should extend beyond sickle cell disease itself.